Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2011
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XE15
|
| gptkbp:CASNumber |
918504-65-1
|
| gptkbp:chemicalFormula |
C23H18ClF2N3O3S
|
| gptkbp:developedBy |
gptkb:Genentech
gptkb:Daiichi_Sankyo |
| gptkbp:genericName |
gptkb:vemurafenib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zelboraf
|
| gptkbp:indication |
metastatic melanoma
unresectable melanoma |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Roche
|
| gptkbp:mechanismOfAction |
BRAF inhibitor
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:cutaneous_squamous_cell_carcinoma
nausea fatigue rash photosensitivity arthralgia |
| gptkbp:target |
gptkb:BRAF_V600E_mutation
|
| gptkbp:usedFor |
treatment of melanoma
|
| gptkbp:bfsParent |
gptkb:Roche
gptkb:vemurafenib |
| gptkbp:bfsLayer |
6
|